This is a website for healthcare professionals.
Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics
How can anti-nuclear antibody (ANA) positive patients who also have undifferentiated connective tissue disease (UCTD) quickly find a diagnosis? Conventional biomarker tests available today can still leave some patients without the required answers to end their diagnostic journey.
In this webinar, you will gain insights into emergent biomarkers for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The speakers will share how novel T Cell biomarkers can offer more confident diagnoses of SLE, particularly when conventional biomarkers are insufficient. Moreover, you will be introduced to a new panel of biomarkers specifically designed to address the diagnostic challenges of seronegative RA, enhancing detection and treatment strategies.
The expert speakers will also share their research into novel biomarkers that can become tools for attendees and help in the confident diagnosis of this challenging patient population.
Listen to this webinar today to learn how clinical biomarkers can help expedite diagnoses and optimize treatment strategies for ANA patients with undifferentiated connective tissue disease.
ACCESS WEBINAR
Dr. George Muñoz, MD, Rheumatologist and Internist, AOTRC-AARA and Larking Rheumatology Program Director
George Muñoz, MD, is BOARD CERTIFIED in Internal Medicine and Rheumatology with a background in Molecular Biology from Columbia College. He has over 25 years’ experience as Clinical Lab Director in Autoimmune testing for AOTRC Rheumatology (Miami, Fl) and serves as an innovator and consultant in the autoimmune testing space and novel biomarker development for industry. He is a Harvard trained Rheumatologist from the Brigham and Beth Isreal Hospitals (Boston, Ma) and currently serves as the Program Director for Miami Larkin Hospital Rheumatology Fellowship Program. As a Founding member of AARA, he is proud to share his expertise in EXAGEN LAB’s NOVEL BIOMARKERS for both Lupus and RA.
Dr. Andrew Concoff, MD, Rheumatologist and Chief Innovation Officer, Exagen Inc.
Dr. Andrew Concoff brings a tremendous range of experience across the rheumatology ecosystem to his dual roles as Chief Innovation Officer at Exagen Inc., where he focuses on biomarker development in rheumatic diseases, as well as Chief Medical Officer for United Rheumatology, where he designs and implements real-world evidence projects and negotiates value-based contracts on behalf of rheumatologists with health plans. His domain expertise spans the gap from the basic and clinical science of rheumatology and sports medicine to biomarker development and implementation designed to improve patient outcomes and the value of care.
After training as one of the few doctors in the nation to have completed fellowships in both rheumatology and sports medicine, Dr. Concoff received a Career Development Award from the NIH for his research in exercise for knee osteoarthritis. He applied this background in a hybrid, orthopedic and rheumatology private practice for 15 years in Southern California. He also served as a Medical Director at a comprehensive wellness center, including supervising the transition to evidence-driven physical therapy, the development of value-based low back pain assessment and treatment program, as well as the development of tissue- and disease-specific rehabilitation protocols and an objective set of criteria to determine a patient’s candidacy for total joint replacement.
Dr. Concoff has remained active in clinical research and teaching. His published research includes big data and health economic analyses in rheumatic diseases as well as guideline development on behalf of numerous medical societies. Dr. Concoff has also served as a Clinical Reviewer for the Institute for Clinical and Economic Review’s (ICER) cost-effectiveness assessments of both targeted synthetic and biologic medications for rheumatoid arthritis.